Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...
Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall Street's most ...
The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback